⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ERNA News
Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
globenewswire.com
ERNA
Three Biotechs Deliver Catalysts to Watch
globenewswire.com
NTHI
ERNA
VIVS
LLY
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
globenewswire.com
ERNA
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
globenewswire.com
ERNA
Form 8-K
sec.gov
ERNAW
ERNA
Form 8-K
sec.gov
ERNAW
ERNA
Form 8-K
sec.gov
ERNA
ERNAW
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
globenewswire.com
ERNA
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
globenewswire.com
ERNA
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
globenewswire.com
ERNA